Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Myocardial Infarction

In brief

This study aims to investigate the effect of early administration of DAPA during ischemia and before pPCI on infarct size, reperfusion injury-related myocardial damage, cardioprotection from HF, and renoprotection from AKI in patients with AMI.

Key facts

Study ID

NCT06009874

Run by

Mohammad Hussien Tantawy Soliman

People needed

80

Starts

2023-10-01

Expected to finish

2026-08-01

Last updated by the study team

2023-08-24

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with ST-elevation myocardial infarction (STEMI).
• STEMI was defined according to the Fourth Universal Definition of AMI.
• 18 - 80 years of age.
• Diabetics or non-diabetics.
• eGFR > 45 ml/min/1.73m2.
• Blood pressure before first drug dosing >110/70 mmHg.

You may not qualify if…

• Cardiogenic shock.
• Hypoglycemia.
• History of diabetic ketoacidosis.
• Genital and urinary infections.
• History of AMI.
• Stent thrombosis.
• Previous coronary artery bypass surgery.
• Severe hepatic insufficiency.
• Advanced cancer patients.
• Blood pH < 7.32.
• Known allergy to SGLT-2 inhibitors.
• Hemodynamic instability.
• Females of childbearing potential without adequate contraceptive methods.
• Patients currently on or have received any SGLT-2 inhibitors.

Where it is running

• Mohammad Soliman — Shibīn al Kawm, Menofia, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.